Travere Therapeutics Inc.

Travere Therapeutics, Inc., a San Diego‑based biopharma, develops rare kidney disease treatments, including orphan‑designated FILSPARI (sparsentan) and Thiola for cystinuria, with a Phase III candidacy and strong NIH and PharmaKrysto partnerships.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 385
HQ: San Diego

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
TVTX	Travere Therapeutics Inc. Cap: 3.1B	EQUITY	NGM	USD	US89422G1076	Active	📈